TROG 12.01 – HPV OROPHARYNX

Dataset Name:

TROG 12.01 – A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV OROPHARYNX)

DOI:

10.58118/k3d6-ez03

Publisher:

TROG Cancer Research

Creator(s):

Danny Rischin

Contributor(s):

Peter McCallum Cancer Centre

Date made available:

2025

Dataset:

Individual Participant Data

Subject (ANZSRC Category):

Radiation therapy

Patient sample size:

189

Dataset Description:

This dataset includes data for 189 trial participants with HPV positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) who took part in the phase 3 multi-centre, open-label randomised trial of weekly cetuximab and RT versus weekly cisplatin and RT for patients with locoregionally advanced HPV-OPSCC. Participants were recruited at sites in Australia and New Zealand and includes data from registration on study, and up to 5 years in follow up. The study commenced in June 2013 and conducted the last patient last visit in Aug 2023. Dataset includes Timepoints at 3, 6, 9, 12 months and yearly to 5 years, QOL, Cancer Australia demographic data includes: Date of birth.

Funding:

NMHRC, TROG

Keywords (MeSH):

ANZCTR Reference:

ACTRN12613000279729

Publications:

Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study

https://pubmed.ncbi.nlm.nih.gov/34098030/

Requests for Data:

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to trials@trog.com.au.

Please submit a New Trial Proposal Application (Category D) to the TROG Cancer Research Operations Executive Committee.